Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Locally Advanced Non-resectable Breast Cancer”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)UnknownNCT05340413
What this trial is testing

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
SOLTI Breast Cancer Research Group 63
Early research (Phase 1)WithdrawnNCT06590558
What this trial is testing

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00633464
What this trial is testing

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
R-Pharm 79
Large-scale testing (Phase 3)Active Not RecruitingNCT05347134
What this trial is testing

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 254
Testing effectiveness (Phase 2)Ended earlyNCT03184558
What this trial is testing

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Who this might be right for
Triple Negative Breast CancerInflammatory Breast Cancer Stage IV
BerGenBio ASA 29
Testing effectiveness (Phase 2)Study completedNCT04464174
What this trial is testing

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
MedSIR 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT05383196
What this trial is testing

Onvansertib + Paclitaxel In TNBC

Who this might be right for
Breast CancerInvasive Breast CancerUnresectable Breast Carcinoma+7 more
Antonio Giordano, MD 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07040644
What this trial is testing

Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Who this might be right for
Triple Negative Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing

Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50
Large-scale testing (Phase 3)Study completedNCT04177108
What this trial is testing

Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Hoffmann-La Roche 242
Large-scale testing (Phase 3)Active Not RecruitingNCT06382142
What this trial is testing

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 418
Testing effectiveness (Phase 2)UnknownNCT05670925
What this trial is testing

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)Looking for participantsNCT05269381
What this trial is testing

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+127 more
Mayo Clinic 36
Large-scale testing (Phase 3)Ended earlyNCT04335006
What this trial is testing

Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06471205
What this trial is testing

BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT05918133
What this trial is testing

PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Who this might be right for
TNBC
Biotheus Inc. 42
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Not applicableActive Not RecruitingNCT07018427
What this trial is testing

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast NeoplasmsTriple Negative Breast CancerHR+, HER2-, Advanced Breast Cancer+1 more
Peking University Cancer Hospital & Institute 70
Load More Results